ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial

ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial

Conditions: Obesity; Liver Diseases; Liver Fibrosis; Liver Fat; NAFLD; Weight Loss; Insulin Resistance; Insulin Sensitivity; Insulin Sensitivity/Resistance; Metabolic Diseases; Diabetes; Diabetes Mellitus, Type 2; Diabetes Mellitus; NASH With Fibrosis; Non-Alcoholic Fatty Liver Disease; Non Alcoholic Fatty Liver; Non-alcoholic Steatohepatitis
Interventions: Device: ESG; Drug: GLP1-RA
Sponsors: Pichamol Jirapinyo, MD, MPH
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 19, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments